[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Biochemistry](https://durgical.com/en/biochemistry/) › Growth factors, their receptors and the kinases behind them

# Growth factors, their receptors and the kinases behind them

Growth factors tell cells to divide, move or survive; most act through [receptor tyrosine kinases](https://durgical.com/en/biochemistry/topics/receptor-tyrosine-kinases/) and a few shared kinase chains, many of them drug targets.

Updated Nov 16, 2026

## How to think about it

Most growth factors are variations on one wiring diagram: a receptor [tyrosine](https://durgical.com/en/biochemistry/molecules/tyrosine/) kinase feeds two shared chains (RAS–MAPK for «divide», PI3K–AKT– [mTOR](https://durgical.com/en/biochemistry/enzymes/mtor/) for «grow and survive»), plus a few special-purpose sensors (HIF for [oxygen](https://durgical.com/en/pharmacology/oxygen/), TGF-β as a brake). Learn the diagram once; then each factor is just «which cell, which job», and each targeted cancer drug is «which node it blocks».

## Key facts

- Most growth factors bind a receptor tyrosine kinase, which activates two main chains: RAS–RAF–MEK–ERK (the MAP kinase pathway) and PI3K–AKT–mTOR.
- Examples: EGF and HER2, PDGF (from platelets, for wound repair and fibrosis), FGF, VEGF and placental growth factor (PlGF, for new vessels), IGF-1 and its receptor ([growth hormone](https://durgical.com/en/pharmacology/classes/growth-hormone/) 's mediator), and HGF with its receptor c-MET.
- c-KIT (CD117) is the receptor for stem cell factor; activating mutations drive gastrointestinal stromal tumours and systemic [mastocytosis](https://durgical.com/en/conditions/mastocytosis/), and [imatinib](https://durgical.com/en/pharmacology/imatinib/) blocks it.
- [Insulin receptor](https://durgical.com/en/biochemistry/enzymes/insulin-receptor/) substrate 1 (IRS-1) is phosphorylated by the insulin receptor and recruits PI3K; its [phosphorylation](https://durgical.com/en/biochemistry/topics/allosteric-and-covalent-regulation-of-enzymes/) on serine in [obesity](https://durgical.com/en/conditions/obesity/) is one mechanism of insulin resistance.
- mTOR activates p70 S6 kinase, which phosphorylates ribosomal protein S6 and boosts [protein synthesis](https://durgical.com/en/biochemistry/topics/translation-and-the-genetic-code/) and cell growth; [sirolimus](https://durgical.com/en/pharmacology/sirolimus/) (rapamycin) blocks mTOR.

## Growth factors at a glance

| Factor | Receptor | Main job | Disease link |
| --- | --- | --- | --- |
| EGF | EGFR (ERBB1) | Epithelial growth and repair | EGFR-mutant [lung cancer](https://durgical.com/en/conditions/lung-cancer/) |
| HER2 (no ligand of its own) | ERBB2, partner of other ERBBs | Amplifies ERBB signals | HER2-amplified breast and [gastric cancer](https://durgical.com/en/conditions/gastric-cancer/) |
| VEGF, PlGF | VEGFR1/2 | New blood vessels | [Tumour angiogenesis](https://durgical.com/en/general-pathology/tumour-angiogenesis/), wet [macular degeneration](https://durgical.com/en/conditions/age-related-macular-degeneration/), pre- [eclampsia](https://durgical.com/en/conditions/eclampsia/) (sFlt-1 excess) |
| PDGF | PDGFR | Fibroblast and smooth-muscle growth, wound repair | Fibrosis, some stromal tumours |
| Stem cell factor | c-KIT (CD117) | Mast cells, germ cells, pacemaker cells of the gut | [GIST](https://durgical.com/en/conditions/gastrointestinal-stromal-tumour/), systemic mastocytosis |
| HGF (scatter factor) | c-MET | Cell scattering and movement | MET-altered lung cancer |

## In detail

- ERK carries growth signals; JNK and p38 are stress-activated kinases switched on by cytokines, ultraviolet light and osmotic stress.
- GSK-3 keeps [glycogen synthase](https://durgical.com/en/biochemistry/enzymes/glycogen-synthase/) inactive; insulin, through AKT, inhibits GSK-3 so [glycogen](https://durgical.com/en/biochemistry/molecules/glycogen/) is made. GSK-3 also controls β-catenin in the Wnt pathway.
- Hypoxia-inducible factor 1α (HIF-1α) is destroyed when oxygen is normal, through the VHL protein; in hypoxia it accumulates and switches on erythropoietin, VEGF and [glycolysis](https://durgical.com/en/biochemistry/pathways/glycolysis/) genes.
- TGF-β slows the growth of epithelial cells and drives fibrosis; many cancers escape its brake.
- HGF, also called scatter factor, makes epithelial cells separate and move; MET amplification or mutation occurs in some lung cancers.

**Also called**
c-KIT, c-MET, IGF-1R and VEGF, MAPK, mTOR and HIF

## What breaks, and the disease it causes

- **Activating c-KIT (or PDGFRA) mutation** → the receptor signals without ligand in the gut's pacemaker cells: gastrointestinal stromal tumour, which responds to KIT inhibitors. [Gastrointestinal stromal tumour (GIST) →](https://durgical.com/en/conditions/gastrointestinal-stromal-tumour/)
- **Loss of VHL** → HIF is never destroyed: VEGF and erythropoietin are switched on, giving vascular clear-cell kidney tumours. [Renal cell carcinoma →](https://durgical.com/en/conditions/renal-cell-carcinoma/)
- **[Placenta](https://durgical.com/en/histology/placenta/) releases excess sFlt-1** → free VEGF and PlGF are trapped and the maternal endothelium suffers: hypertension and proteinuria. [Preeclampsia →](https://durgical.com/en/conditions/preeclampsia/)

## Clinical notes

- Loss of VHL keeps HIF active and causes clear-cell renal carcinoma and haemangioblastomas.
- A high ratio of soluble Flt-1 (a VEGF trap) to PlGF in the mother's blood helps predict pre-eclampsia.
- [Kinase inhibitors](https://durgical.com/en/pharmacology/classes/kinase-inhibitors/) and monoclonal [antibodies](https://durgical.com/en/biochemistry/enzymes/immunoglobulins/) against these receptors (anti-EGFR, anti-HER2, anti-VEGF, KIT inhibitors) are central to modern cancer treatment.

## Common traps

- Each growth factor has its own private pathway: most converge on the same two chains (MAPK and PI3K–AKT–mTOR); what differs is the receptor, the cell and the job.
- HER2 is activated by its own ligand: HER2 has no known ligand; it is the preferred partner of other ERBB receptors, and amplification lets it signal by mass.
- TGF-β is a growth factor, so it always promotes tumours: in normal epithelium it slows division; tumours escape its brake, and later it also promotes fibrosis and invasion.
- HIF is controlled at the gene level: it is made all the time but destroyed in normal oxygen via VHL; hypoxia or VHL loss lets it accumulate.

## Test yourself

Think of the answer, then tap the question to see it.

## Which two signalling chains do most growth-factor receptors activate?

RAS–RAF–MEK–ERK (MAP kinase) and PI3K–AKT–mTOR.

## What happens to HIF-1α when oxygen is low?

It is no longer destroyed via VHL, so it accumulates and switches on genes such as erythropoietin and VEGF.

## A patient has a gastric wall tumour that stains strongly for CD117 (c-KIT). Why does a KIT kinase inhibitor shrink it?

Most GISTs carry an activating KIT (or PDGFRA) mutation that signals without ligand; blocking the receptor's kinase removes the growth signal the tumour depends on.

## A pregnant woman at 32 weeks has new hypertension and a high sFlt-1/PlGF ratio. What is the mechanism?

The stressed placenta releases soluble Flt-1, which traps VEGF and PlGF; the maternal endothelium loses this survival signal, leading to vasoconstriction, hypertension and proteinuria (pre-eclampsia).

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/biochemistry/topics/growth-factors-their-receptors-and-the-kinases-behind-them/)

## Connections

## Related conditions 2

- [Gastrointestinal stromal tumour (GIST)](https://durgical.com/en/conditions/gastrointestinal-stromal-tumour/)
- [Preeclampsia](https://durgical.com/en/conditions/preeclampsia/)

## Related 5

- [Receptor tyrosine kinases](https://durgical.com/en/biochemistry/topics/receptor-tyrosine-kinases/)
- [Insulin signalling](https://durgical.com/en/biochemistry/topics/insulin-signalling/)
- [mTOR (mechanistic target of rapamycin)](https://durgical.com/en/biochemistry/enzymes/mtor/)
- [Oncogenes and tumour suppressor genes](https://durgical.com/en/biochemistry/topics/oncogenes-and-tumour-suppressor-genes/)
- [Glycogen synthase](https://durgical.com/en/biochemistry/enzymes/glycogen-synthase/)

Educational information, not medical advice. For any symptom, see a health professional.

Sources: [KIT: Mast/stem cell growth factor receptor Kit (human)](https://www.uniprot.org/uniprotkb/P10721/entry) (UniProt, 2026); [MET: Hepatocyte growth factor receptor (human)](https://www.uniprot.org/uniprotkb/P08581/entry) (UniProt, 2026); [HIF1A: Hypoxia-inducible factor 1-alpha (human)](https://www.uniprot.org/uniprotkb/Q16665/entry) (UniProt, 2026); [RPS6KB1: Ribosomal protein S6 kinase beta-1 (human)](https://www.uniprot.org/uniprotkb/P23443/entry) (UniProt, 2026); [IRS1: Insulin receptor substrate 1 (human)](https://www.uniprot.org/uniprotkb/P35568/entry) (UniProt, 2026).

[← All of biochemistry](https://durgical.com/en/biochemistry/)

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/biochemistry/topics/growth-factors-their-receptors-and-the-kinases-behind-them/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/biochemistry/topics/growth-factors-their-receptors-and-the-kinases-behind-them/
